PolynucleotidesFor fine lines and crepey skin.

It means the qualities visible at close range: elasticity, texture, fine crepiness, hydration and light-reflection. Polynucleotides aim at those qualities — not volume, contour, projection or true laxity.

They may be considered for crepiness and elasticity of thin under-eye skin, texture and fine wrinkling of the face, neck or décolletage, and skin-quality change where filler would be the wrong tool — including where hydration alone is not enough or you are unsuitable for, or finished with, HA. The periorbital area is the best-studied aesthetic site, although the evidence remains small, product-specific and uncertain.⁴⁵

They do not replace SPF, sleep or treatment of the actual underlying cause.

Published reviews distinguish several contributors to an under-eye concern, including volume loss, pigment, visible vessels, skin laxity and other structural factors. More than one contributor may be present at the same time. Current polynucleotide evidence aligns most directly with texture and fine rhytides; it does not establish correction of volume loss, pigment, vascular colour or structural shadow. ⁸ Persistent puffiness or bags need separate assessment before treatment. Polynucleotides are considered for skin texture and fine lines; they do not remove an eye bag. Injections can cause swelling, so existing puffiness matters when deciding whether treatment is suitable.⁵

Treatment at odNOVA is for adults aged 18 and over. A reasonable fit may be someone with crepey, thinning under-eye or facial skin, patience for gradual change, and acceptance that the evidence is emerging and a visible response is not guaranteed. Age alone does not decide suitability.

It is usually the wrong step when the real concern is hollowing, bags, pigment or laxity, or when you need a visible result by a fixed date.

PDRN generally refers to shorter, lower-molecular-weight fragments. PN generally refers to longer, higher-molecular-weight and more viscous chains thought to act for longer. Terminology, purification and formulations are not standardised, so one product’s result does not automatically apply to another.⁷

One proposed action is that DNA fragments break down into smaller components that cells can reuse during repair. This is known as the salvage pathway. Much of the mechanistic research concerns PDRN in laboratory models; it does not establish that every PN product works in the same way.⁷ Human aesthetic studies report changes in skin properties, but products, treatment methods and measures differ. There is no agreed dose or interval for the whole category.¹²

• HA skin booster: mainly hydration and dermal water.
• PRP or PRF: a preparation from your own blood.
• Microneedling: a device-created controlled injury, not an injected material. It can be complementary, but it works differently.
• Biostimulator: diffuse collagen support that develops over months where structural support has been lost.
• HA filler is used to add volume and shape. Polynucleotides are considered for skin texture and fine lines. The treatments address different problems, so one cannot simply replace the other.

The polynucleotide or PDRN material is usually derived from salmon or trout DNA. Purification does not change the fact that the source is animal-derived. Source and composition are confirmed for the specific product considered.

A fish allergy may make a polynucleotide product unsuitable. The decision depends on the exact formulation, its instructions for use and your allergy history. Treatment does not go ahead if you have an allergy incompatible with the chosen product.

You do not need to justify that preference. PRP or PRF, prepared from your own blood, may be discussed where clinically appropriate, as may a skin booster, microneedling, skincare or no procedure. These are not interchangeable substitutes; each answers a different question.

Whether the concern is caused mainly by skin quality, volume, pigment, fluid or structure. I review medical and allergy history, photographs, the exact product and its instructions, evidence limits and a realistic objective. Where polynucleotides fit, one treatment may be booked; any later session is a separate clinical decision. Where they do not, I say so plainly.

The under-eye and nose are anatomically sensitive. It is reasonable to ask about clinical background, how the practitioner diagnoses the concern, how products are selected, which exact product is proposed and how complications are managed.

I use polynucleotides and find them an interesting addition to skin-quality treatment. I am also clear that the evidence is early and not every “tired eye” will improve. I would rather tell you that the concern is a hollow or pigment this treatment will not fix than recommend a treatment that was never going to work.

Arrive without active infection or irritation in the area. Discuss blood-thinning medicines and supplements beforehand. Avoid alcohol and vigorous exercise the day before to reduce bruising. For an important event, leave at least one week — ideally two.

The planned area is photographed and agreed, topical numbing is applied, the skin is cleansed and the material is placed in a series of small deposits. The area and technique are individual to assessment and consented before treatment. If another session may be useful, that is decided separately after reassessment.

Small raised injection bumps, swelling, redness and tenderness can occur.⁵ Their appearance depends on the product and injection method. These early effects often settle within roughly 24–72 hours, although bumps or swelling can last longer and may need review. Bruising may remain after the early swelling settles.

No makeup on the treated area until the next day. Avoid sauna, swimming and intense exercise for 24–48 hours. After under-eye treatment, sleeping slightly elevated may reduce morning swelling. Follow the individual aftercare note supplied for your treatment.

Published studies do not establish reliable one-in-X frequencies across products. Risk depends on product, depth, volume, area, technique and individual healing.

Risk reduction starts with patient selection, sterile technique and clear aftercare. I review the area, medical and allergy history, medicines, the exact product, planned depth and volume before treatment. Active infection or inflammation means treatment waits. Technique is adapted to the anatomy, but no facial injection can be made risk-free.

Infection, cold-sore reactivation and post-inflammatory pigment change remain possible in susceptible skin even with appropriate precautions. Written aftercare explains what is expected, what is not, and how to contact the clinic.

• Known allergy incompatible with the chosen product, including relevant fish allergy.
• A personal decision to avoid animal-derived fish products.
• Active infection, inflammation or skin disease in the treatment area.
• Pregnancy or breastfeeding — treatment is postponed.
• A bleeding disorder or blood-thinning medicine that has not been individually reviewed.
• A concern that is actually volume, bags, pigment or true laxity rather than skin quality.
• Inability to accept a gradual, variable and not-yet-fully-proven result, including possible non-response.

Medical and allergy history, prescribed medicines, supplements, bleeding risk, previous reactions, skin condition and the exact proposed product. The product’s current instructions and UK status must be checked for the intended area and use. Do not stop prescribed medication for an aesthetic appointment unless the clinician managing it advises you to.

Yes. Suitability is not only a contraindication checklist. A technically possible treatment can still be the wrong choice if the diagnosis, likely scale of benefit, timing, cost or uncertainty does not fit you.

No. Published studies may describe two- or three-session protocols, but that research schedule does not commit you to a series. Each appointment stands alone. Another appointment is discussed only after reassessment and remains a separate, individually priced decision.

Once the initial swelling settles, there may be little immediate change. Any improvement develops over weeks. In one study of 42 people using Pluryal Silk around the eyes, patient-reported improvement was greatest around three months after a two-session protocol. Scores remained above baseline at six months, although slightly lower than at three months.⁵ This uncontrolled study does not establish one timetable for everyone.

The concern may not truly be a skin-quality problem; product, protocol, skin condition and lifestyle differ; and the evidence is not strong enough to predict individual response. Some people see little or no visible change.

How long a gain persists is not reliably established. Available studies are mostly small, uncontrolled and short-term.

Possibly, but it is not automatic. A later appointment is considered only if review shows a worthwhile response and it remains clinically justified. No universal interval is established.